Stocks and Investing
Stocks and Investing
Tue, June 11, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Serge Belanger Reiterated (VRDN) at Strong Buy and Held Target at $30 on, Jun 11th, 2024
Serge Belanger of Needham, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $30 on, Jun 11th, 2024.
Serge has made no other calls on VRDN in the last 4 months.
There are 6 other peers that have a rating on VRDN. Out of the 6 peers that are also analyzing VRDN, 2 agree with Serge's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kalpit Patel of "B. Riley Securities" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Thursday, May 9th, 2024
- Michael Higgins of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Thursday, May 9th, 2024
These are the ratings of the 4 analyists that currently disagree with Serge
- Richard Law of "Goldman Sachs" Initiated at Strong Buy and Held Target at $23 on, Thursday, June 6th, 2024
- Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $27 on, Thursday, May 9th, 2024
- Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $31 on, Thursday, May 9th, 2024
- Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $40 on, Wednesday, February 28th, 2024
Contributing Sources